Shire Pharmaceuticals Group Plc
Shire Announces Top-line Results of the PREVENT2 Trial
Philadelphia, Pennsylvania (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX(R) mesalamine in patients with a history of diverticulitis.[1] The study, conducted in 10 countries worldwide including the United States, did not meet the primary endpoint in reducing the rate of ...
mehr